Realtime | Geld | Brief | Zeit |
---|---|---|---|
4,880 | 5,200 | 20:33 | |
4,900 | 5,150 | 20:32 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | KEYMED BIO-B (02162): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2025 | - | HKEx | ||
19.06. | KEYMED BIO-B (02162): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
19.06. | KEYMED BIO-B (02162): COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE | - | HKEx | ||
13.06. | Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine | 575 | PR Newswire | CHENGDU, China, June 13, 2025 /PRNewswire/ -- On June 12, Keymed Biosciences Inc. (HKEX: 02162) announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases... ► Artikel lesen | |
11.06. | KEYMED BIO-B Places Shrs at 6.5% Discount to Raise HKD850M+ Net Proceeds; Controlling Shareholder Cuts Stake | 1 | AASTOCKS | ||
11.06. | KEYMED BIO-B (02162): (1) PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE AND (2) SALE OF SHARES BY THE TOP-UP ... | 1 | HKEx | ||
KEYMED BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
28.04. | KEYMED BIO-B (02162): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | - | HKEx | ||
28.04. | KEYMED BIO-B (02162): NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx | ||
28.04. | KEYMED BIO-B (02162): (1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) RE-APPOINTMENT OF AUDITOR; AND (4) ... | - | HKEx | ||
28.04. | KEYMED BIO-B (02162): 2024 ANNUAL REPORT | - | HKEx | ||
27.04. | Keymed Biosciences gibt die IND-Genehmigung für CM518D1 durch die National Medical Products Administration of China zur Behandlung von Solide Tumoren bekannt | 77 | PR Newswire | CHENGDU, China, 27. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" oder das "Unternehmen") gab vor kurzem bekannt, dass CM518D1, ein... ► Artikel lesen | |
25.04. | Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors | 299 | PR Newswire | CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed... ► Artikel lesen | |
07.04. | Keymed Biosciences: Daten aus Phase-III-Studie zu Stapokibart gegen saisonale allergische Rhinitis in Nature Medicine veröffentlicht | 228 | PR Newswire | CHENGDU, China, 7. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" oder "Unternehmen") gab heute bekannt, dass die renommierte medizinische... ► Artikel lesen | |
05.04. | Keymed Biosciences: The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine | 635 | PR Newswire | CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published... ► Artikel lesen | |
26.03. | Keymed Biosciences Announces Annual Results of 2024 | 132 | PR Newswire | CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate... ► Artikel lesen | |
24.03. | KEYMED BIO-B (02162): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
24.03. | KEYMED BIO-B (02162): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
24.03. | KEYMED BIO-B (02162): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024; AND CHANGE OF COMPOSITION OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
12.03. | KEYMED BIO-B (02162): DATE OF BOARD MEETING | 2 | HKEx | ||
10.02. | Keymed's Stapokibart approved by NMPA for seasonal allergic rhinitis | 1 | Pharmaceutical Technology |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 46,985 | -0,01 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
KYMERA THERAPEUTICS | 44,030 | -3,70 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Evotec Aktie mit Verkaufssignal: Konter oder Sturz auf 5 Euro? | Die Evotec Aktie hat am Donnerstag ein charttechnisches Verkaufssignal ausgelöst. Mit einem XETRA-Schlusskurs von 6,568 Euro fiel der Kurs um mehr als vier Prozent und unterschritt dabei mehrere relevante... ► Artikel lesen | |
ADMA BIOLOGICS | 18,250 | -0,71 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
RECURSION PHARMACEUTICALS | 5,050 | -6,65 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
BIONTECH | 90,85 | +0,22 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
ONCO-INNOVATIONS | 1,360 | +8,80 % | EQS-Media: Onco-Innovations Ltd.: Erhebliche Aufwärtsperspektive für frühe Investoren? Neue Studie unterstützt die Anwendbarkeit der Ergebnisse klinischer Lungenkrebsstudien | EQS-Media / 21.06.2025 / 15:37 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass die Mitbegründer seiner hundertprozentigen... ► Artikel lesen | |
VOR BIOPHARMA | 1,085 | +21,91 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
NUVALENT | 81,90 | +3,36 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,860 | -2,11 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target | ||
CITIUS ONCOLOGY | 4,410 | +27,83 % | Citius Oncology Inks Distribution Services Agreement With Cardinal Health For LYMPHIR | WASHINGTON (dpa-AFX) - Citius Oncology, Inc. (CTOR), the oncology-focused subsidiary of late-stage biopharmaceutical company Citius Pharmaceuticals, Inc. (CTXR), announced Monday it has entered... ► Artikel lesen | |
ARCELLX | 66,04 | +1,93 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ARS PHARMACEUTICALS | 18,580 | +2,71 % | ARS Pharmaceuticals, Inc. - 8-K, Current Report | ||
ARCUTIS BIOTHERAPEUTICS | 13,990 | -2,78 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen |